We would like to thank our partners for offering prizes to our participants!
Eligibility
Conditions to be eligible for these prices are:
- Participant must be less than 35 years old
- Less than 10 years since last degree
- Confirm your participation by ticking the appropriate box in the abstract submission form
Prizes
The following prices will be distributed:
Oral communication Prize – JPBA
1 prize of CHF 500 (JPBA)
Young Scientist Short Oral Presentations
1 prize of CHF 400 (PBA 2024)
Flash Poster Prize – ccCTA
1 prize of CHF 300 (ccCTA)
Poster Prizes – Bracco & ccCTA
2 prizes of CHF 300
2 prizes of CHF 200
Bracco Imaging S.p.A. (“Bracco Imaging”), part of the Bracco Group, is an innovative world leader delivering end-to-end products and solutions through its comprehensive portfolio across diagnostic imaging modalities. Headquartered in Milan, Italy, Bracco Imaging’s purpose is to improve people’s lives by shaping the future of prevention and precision diagnostic imaging. Bracco Imaging portfolio includes products and solutions for all key diagnostic imaging modalities: X-ray imaging, magnetic resonance imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine. In 2019 Bracco Imaging also enriched its product portfolio by expanding the range of oncology nuclear imaging solutions in the urology segment and other specialties with the acquisition of Blue Earth Diagnostics. The company is active in molecular imaging with innovative agents for positron emission tomography (PET) in patients with suspected recurrent prostate cancer. The group owns more than 2,000 patents and invests more than 9% of its turnover in diagnostic imaging and advanced devices in research and development each year. Bracco Suisse SA is a research and production center that is part of Bracco Imaging Spa. Bracco Suisse SA has been established in the canton of Geneva for 35 years. The Plan-les-Ouates site includes a research and development (R&D) center and a production unit. The latter is responsible for the manufacture of the ultrasound contrast agent SonoVue®, which was developed by Bracco Switzerland R&D. The team is composed of more than 120 employees. To learn more, visit www.braccoimaging.com
The Centre de Compétence en Chimie et Toxicologie Analytiques (ccCTA) currently brings together 13 laboratories and institutes in the Lake Geneva region.
The fundamental aim of the Center’s partners is to improve knowledge in the fields of analytical chemistry and toxicology, and to develop modern analytical methods for the determination of drugs and medications present in various matrices: biological fluids, injectable solutions, tablets, etc…
This journal is an international medium directed towards the needs of academic, clinical, government and industrial analysis by publishing original research reports and critical reviews on pharmaceutical and biomedical analysis. It covers the interdisciplinary aspects of analysis in the pharmaceutical, biomedical and clinical sciences, including developments in analytical methodology, instrumentation, computation and interpretation. Submissions on novel applications focusing on drug purity and stability studies, pharmacokinetics, therapeutic monitoring, metabolic profiling; drug-related aspects of analytical biochemistry and forensic toxicology; quality assurance in the pharmaceutical industry are also welcome.